Zerokuf Syrup is a combination pharmaceutical formulation containing Ambroxol (15mg), Guaifenesin (50mg), and Terbutaline (1.5mg) per dose, designed to provide effective relief in respiratory conditions characterized by excessive mucus production and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby enhancing expectoration. Guaifenesin serves as an expectorant, promoting the hydration and loosening of bronchial secretions to aid in their expulsion. Terbutaline, a selective beta-2 adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscles, thus alleviating bronchospasm and improving airflow. The synergistic action of these components makes Zerokuf Syrup suitable for managing acute and chronic respiratory disorders such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) where mucus hypersecretion and airway constriction are prominent. It is indicated for patients requiring symptomatic relief from cough with thick mucus and wheezing. Administration should follow medical guidance, considering contraindications such as hypersensitivity to any component, cardiovascular disorders, and hyperthyroidism. Common side effects may include gastrointestinal discomfort, tremors, or palpitations. Zerokuf Syrup should be used with caution in pediatric and geriatric populations, and dosage adjustments may be necessary based on clinical response.